Retevmo®
selpercatinib capsules
40 mg • 80 mg

The Lilly Oncology Support Center + Retevmo

Support Tailored for a Patient's Retevmo Treatment Journey*

The Lilly Oncology Support Center is committed to helping qualified patients when they're prescribed a Lilly Oncology product. We focus on financial and coverage issues, offering resources and individualized support for eligible patients, whether they're uninsured, underinsured, or insured. The Lilly Oncology Support Center can provide guidance for uninsured/under-insured patients on alternative funding sources. Services include: help with benefit verification, prior authorization, paying for medicine, and specialty pharmacy coordination.

The Lilly Oncology Support Center can also provide support beyond financial assistance for certain products, and help patients connect with non-Lilly resources, such as therapeutic support groups for specific types of cancer.



Retevmo Insurance & Coverage Assistance*

May help eligible patients minimize co-pay or out-of-pocket costs by providing:

- A benefits investigation
- Guidance through the specialty pharmacy process
- Identification of savings opportunities



Retevmo Interim Access Program

- The Retevmo Interim Access Program may provide a temporary supply of Retevmo at no cost to insured, eligible patients who have been prescribed Retevmo for the first time and are experiencing a delay in their insurance coverage decision†



Retevmo Savings Card Program

- Eligible commercially insured covered patients pay as little as $0 a month‡
- Digital cards can be downloaded online. You and your patients can get a savings card by visiting Retevmo.com for Savings and Support offerings



MyRightDose: Dose Exchange Program§

May simplify midcycle dose exchanges for patients—MyRightDose ships the appropriate dose directly to your patient's home in as early as 48 hours and at no cost to the patient



Retevmo Ongoing Support*

Dedicated support staff: patients speak to the same person every time. The Companion in Care™ can help patients by:

- Providing emotional support when patients need it
- Reiterating treatment information when taking Retevmo

The Companion in Care™ does not replace a trained healthcare provider; when medical questions arise, your patients will always be directed back to your office

HIPAA=Health Insurance Portability and Accountability Act.

*Retevmo Support programs and offerings are not a guarantee of coverage. Terms and conditions apply for all programs. See enrollment form for details.

†**TERMS AND CONDITIONS:** The Retevmo Interim Access Program (or "Program") provides a 15-day supply of Retevmo at no charge for eligible, insured patients who are: 1) prescribed Retevmo for the first time after testing positive for a *RET* alteration, 2) experiencing a minimum 5-business-day delay in insurance coverage determination, 3) prescribed Retevmo for an FDA-approved indication or an indication medically supported by CMS-recognized compendia, and 4) enrolled in the Lilly Oncology Support Center, 5) residents of the United States or Puerto Rico. May not be combined with any other offer. Not available to patients whose insurers have made a final determination to deny the patient coverage for Retevmo. If a denial is received after the initial 5 business days have passed and appeal rights are being pursued, or if there is a persistent coverage delay, the patient, under appropriate circumstances, may be eligible for up to 3 additional 15-day supplies of Retevmo. Product provided through the Program is only available through the Program non-commercial specialty pharmacy. Product is provided free of charge and may not be sold, bartered, or returned for credit. Reimbursement cannot be sought from any third party for product provided under the program. Patients enrolled in Medicare Part D are prohibited from counting any portion of the cost of the product provided under the Program towards true out-of-pocket ("TrOOP") costs for prescription drug calculations. No purchase contingency or other obligation accompanies program participation. This Program is not health insurance and does not guarantee coverage. Lilly reserves the right to change or end the program at any time. Benefits under the program are not transferable.

‡**TERMS AND CONDITIONS:** Offer good for up to 12 months until 12/31/2021. Patients must have coverage for Retevmo through their commercial drug insurance to pay as little as $0 for a 30-day supply of Retevmo. Offer subject to a monthly cap of wholesale acquisition cost plus usual and customary pharmacy charges and a separate annual cap of $25,000. Participation in the program requires a valid patient HIPAA authorization. Patient is responsible for any applicable taxes, fees, or amounts exceeding monthly or annual caps. **This offer is invalid for patients without commercial drug insurance or whose prescription claims for Retevmo are eligible to be reimbursed, in whole or in part, by any governmental program, including, without limitation, Medicaid, Medicare, Medicare Part D, Medigap, DoD, VA, TRICARE®/CHAMPUS, or any state patient or pharmaceutical assistance program.** Offer void where prohibited by law and subject to change or discontinue without notice. Card activation is required. Subject to additional terms and conditions, which can be found at Retevmo.com.

§Additional terms and conditions apply. See the MyRightDose enrollment form for details.

The Role of Field Reimbursement Managers



Field Reimbursement Managers (FRMs) help the healthcare provider (HCP) and their staff navigate the complex access and reimbursement landscape for Lilly Oncology medications to help eligible patients receive Retevmo and begin their treatment as soon as possible.

- Educate HCP offices responsively on reimbursement, patient access, and Lilly's customer support and patient assistance programs
- Provide information to facilitate patient access to prescribed Lilly medications

Enrolling in the Retevmo Savings & Support Programs

To enroll your eligible patients in all or any of these support programs,*
please visit **https://www.retevmo.com/hcp/savings-support**
or call the **Lilly Oncology Support Center** at **1-866-472-8663, Monday–Friday, 8:00 AM–10:00 PM Eastern Time (ET).**

*Retevmo Savings programs and offerings are not a guarantee of coverage. Terms and conditions apply for all programs. See enrollment form for details.

The Lilly Oncology Support Center

In 2020, LillyOncologySupportCenter.com replaced LillyPatientOne.com, providing a one-stop Lilly Oncology customer-support resource for healthcare professionals and patients.

The Lilly Oncology Support Center is open daily from 8:00 AM to 10:00 PM ET.

- **Telephone: 1-866-472-8663**
- **Fax: 1-877-366-0585**

The site offers information about access and reimbursement support programs for all infused and oral Lilly Oncology products.

Retevmo® is a registered trademark and Companion in Care™ is a trademark owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.
TRICARE® is a registered trademark of the Department of Defense (DoD), DHA.
PP-SE-US-0497 12/2020 © Lilly USA, LLC 2020. All rights reserved.

Lilly

Retevmo®
selpercatinib capsules
40 mg • 80 mg